|
Originally published In Press as doi:10.1074/jbc.M110800200 on December 17, 2001
J. Biol. Chem., Vol. 277, Issue 10, 7831-7837, March 8, 2002
The Activation of RalGDS Can Be Achieved Independently of Its
Ras Binding Domain
IMPLICATIONS OF AN ACTIVATION MECHANISM IN Ras EFFECTOR
SPECIFICITY AND SIGNAL DISTRIBUTION*,
Thomas
Linnemann ,
Christina
Kiel,
Peter
Herter, and
Christian
Herrmann§
From the Abteilung Strukturelle Biologie, Max-Planck-Institut
für Molekulare Physiologie, Otto-Hahn-Strasse 11, Dortmund 44227, Germany
Received for publication, November 12, 2001
 |
ABSTRACT |
Small GTPases of the Ras family are major players
of signal transduction in eukaryotic cells. They receive signals from a number of receptors and transmit them to a variety of effectors. The
distribution of signals to different effector molecules allows for the
generation of opposing effects like proliferation and differentiation.
To understand the specificity of Ras signaling, we investigated the
activation of RalGDS, one of the Ras effector proteins with
guanine-nucleotide exchange factor activity for Ral. We determined the
GTP level on RalA and showed that the highly conserved Ras binding
domain (RBD) of RalGDS, which mediates association with Ras, is
important but not sufficient to explain the stimulation of the exchange
factor. Although a point mutation in the RBD of RalGDS, which abrogates
binding to Ras, renders RalGDS independent to activated Ras, an
artificially membrane-targeted version of RalGDS lacking its RBD could
still be activated by Ras. The switch II region of Ras is involved in
the activation, because the mutant Y64W in this region is impaired in
the RalGDS activation. Furthermore, it is shown that Rap1, which was
originally identified as a Ras antagonist, can block Ras-mediated
RalGDS signaling only when RalGDS contains an intact RBD. In addition,
kinetic studies of the complex formation between RalGDS-RBD and Ras
suggest that the fast association between RalGDS and Ras, which is
analogous to the Ras/Raf case, achieves signaling specificity.
Conversely, the Ras·RalGDS complex has a short lifetime of
0.1 s and Rap1 forms a long-lived complex with RalGDS, possibly
explaining its antagonistic effect on Ras.
 |
INTRODUCTION |
Ras is known as a major regulator of cell growth, development, and
the cell cycle. Ras binds tightly to GDP or GTP, and this conversion
between both nucleotide states is strictly controlled and involves
conformational changes in two regions of the protein. Therefore, Ras
behaves like a molecular switch. The active GTP state of Ras signals to
different protein cascades. In the past Raf, phosphatidylinositol
3-kinase (PI3K1), and members
of the RalGDS family were described as effectors of Ras, and a
similar relationship is proposed for other proteins like AF6 or Rin (1,
2). Because Ras is tethered to the plasma membrane through its lipid
modifications, the effectors are recruited to the plasma membrane.
Ras can initiate different effects like proliferation and
differentiation. In many systems Raf signaling via extracellular regulated kinase is sufficient for cell transformation (3). Oncogenic properties are also demonstrated for PI3K and RalGDS, albeit
weaker (4, 5), and suppression of these protein functions can partly
block transformation by Ras (6, 7). In other primary cells the opposite
effects, cell cycle arrest and cell differentiation, are induced by
active Ras (8). In the neuroblastoma cell line PC12, the activation of
the Raf and PI3K branch of Ras signaling transmits the nerve growth
factor signal to finally induce neurite outgrowth (9). In
contrast, the RalGDS branch blocks this differentiation and keeps the
cell in a proliferative state (10).
Members of the RalGDS family have guanine-nucleotide exchange factor
(GEF) activity for RalA and RalB (11). The members of this
family, RalGDS, Rgl, and Rlf, have a C-terminal Ras binding domain (RBD). Rgr, another member, was identified as part of a fusion
protein, which confers tumor-forming activity on NIH3T3 cells (12).
The small Ras-related GTPase Rap1 was originally identified as a Ras
antagonist (13), and this finding was confirmed in other studies
(14-19). Recent findings show that direct functions are the control of
development and cell morphology (20). The interaction between Rap1 and
RalGDS-RBD is the tightest interaction seen for a Ras family member and
an effector RBD (21). In reconstituted lipid vesicle systems a
stimulation of the RalGDS effector pathway could be achieved and was
interpreted as the Rap1-induced co-localization of RalA and RalGDS on
the artificial lipid membranes (22). In experiments with COS7
cells it was not possible to demonstrate any stimulatory effect of Rap1
on RalGDS (7). This was interpreted with different localizations of
Rap1 and RalA (23). However, other studies have clearly shown that Rap1
is found at the plasma membrane and membranes of specialized vesicles
(24-27). Furthermore, RalA is not solely localized at the plasma
membrane but is also found in intracellular vesicles (28). Therefore,
cellular localizations of Rap1 and Ral do not exclude a functional
cascade of Rap1, RalGDS, and Ral. Another explanation for the inability
of Rap1 to activate RalGDS could be seen in an activation mechanism as
described for Raf kinase (29) and PI3K (30). In such a scenario, RalGDS could be recruited to the plasma membrane by Ras and additionally activated; Rap1 would only be able to bind RalGDS. To test this hypothesis we have analyzed different constructs of RalGDS and demonstrated an RBD-independent activation mechanism, which involves the switch II region of Ras. Kinetic studies support the notion that
the Ras switch has evolved to control the association speed of effector
complex formation (31). The latter can be reconciled with the finding
that the lower affinity interaction between Ras and RalGDS is
sufficient for signal transmission. A comparison with other RBDs
prompted us to conclude that the high affinity between Rap1 and RalGDS
could be important for the inhibition of this signaling branch of Ras.
 |
MATERIALS AND METHODS |
Plasmids--
pBSK:mRalGDS, containing the RalGDS cDNA from
mouse, was kindly provided by Dr. R. A. Weinberg. The whole
cDNA, including the 5'-untranslated region was sub-cloned with
EcoRI/Aat2 after removal of the 5'-overhang from
the Aat2 restriction site into EcoRI/EcoR5-digested pcDNA3 to yield
pcDNA3:mRalGDS. The K835A variant of RalGDS was generated according
to the PCR mutation protocol of Picard et al. (32).
pcDNA3:RalGDS, which contained a Myc-tag, was obtained with
two PCR templates between the primers
5'-GCGGAATTCGCGGCCGCG/5'-CCGGGTACCTATAGGTCCTCCTCGGAGATCAGCTTCTGCTCCATCCTCAGCCTCGG and 5'-CCGGAATTCAGGACCTGGAAGTAGATTGCCAG/5'-CGGGGTACCTCTAGAGGAGGC. Fragments were amplified from pBSK:mRalGDS and sub-cloned via EcoRI/KpnI digestion into pBKS. The first PCR
template was ligated in front of the second with
EcoRI/EcoO109 yielding an N-terminal construct of
RalGDS, which contains the whole 5'-untranslated region, and a
c-Myc-tag at the N terminus. The two original Met start codons of
RalGDS are deleted in this construct. This fragment was sub-cloned with
EcoRI/XbaI digestion into pcDNA3:RalGDS using only the N-terminal XbaI restriction site in
pcDNA3:RalGDS.
To generate pcDNA3:RalGDS RBD the XhoI restriction
site in pBKS:mRalGDS was removed with a XhoI/SalI
digestion followed by religation (= pBKS:mRalGDS XhoI).
The RBD was removed from this construct with
PstI/Aat2 digestion and an oligonucleotide linker comprising 5'-GCTACAGCGTTAACTAACTCGAGGACGT and
5-CCTCGAGTTAGTTAACGCTGTAGCTGCA was ligated into this plasmid (=
pBKS:mRalGDS RBD). Sub-cloning of a fragment from pBKS:mRalGDS RBD
to pcDNA3:RalGDS with PshA1/XhoI digestion
resulted in pcDNA3:RalGDS RBD.
RalGDS-RBD was introduced into pcDNA3:RalGDS RBD with a PCR
fragment amplified from pBKS:mRalGDS between the primers
5'-GGTCTGCAGCTACAGCTC and 5'-CCGCTCGAGTTAGTTAACGGTCCGCTTC. The PCR
fragment was then ligated with PstI/XhoI into
pBKS:mRalGDS RBD. The resulting pBKS:mRalGDS* does not contain the
last 30 amino acids of RalGDS. Sub-cloning a
PshA1/XhoI fragment from pBKS:mRalGDS* into
pcDNA3:Myc-mRalGDS led to pcDNA3:RalGDS*.
The C terminus from Ki-Ras, including the
CAAX box, was attached to the RalGDS sequences via a PCR
fragment amplified from ptac:K-ras (provided by Dr. A. Wittinghofer)
between the primers 5'-CGCGGATCCGTTAACAAAGATGGTA and
5'-CCGCTCGAGTTACATAATT. The amplified sequence was ligated to
pBKS:mRalGDS* and pBKS:mRalGDS RBD between the restriction sites
HpaI and XhoI. The CAAX-modified
RalGDS sequences were sub-cloned with PshA1/XhoI
to pcDNA3:RalGDS to yield pcDNA3:RalGDS*CAAX and
pcDNA3:RalGDS RBD-CAAX, respectively.
pMT2:RalA was kindly provided by Dr. G. J. T. Zwartkruis,
pSVK3:Ras G12V and the double mutants G12V/Y64W and G12V/E37G in the
same expression vector were provided by Dr. C. Block. pcDNA3:Rap1A G12V was obtained from Dr. A. Wittinghofer. All constructs were verified by sequence analysis.
Cell Culture and Transfection Assay--
COS7 cells were grown
in DMEM (without pyruvate, with pyridoxin and Glutamax-1, Invitrogen)
and 10% FCS (Pan-Biotech). The cells were transfected with activated
dendrimers (SuperFect, Qiagen) in 6-cm dishes. 5-6 µg of DNA was
diluted with 125 µl of DMEM, and 20 µl of SuperFect reagent was
added. The cells were incubated with this transfection solution for
4 h and then incubated in medium with 10% FCS for 24 h. The
RalA loading assay was carried out as described previously (5).
Briefly, 24 h after transfection the COS7 cells were grown
overnight in DMEM with 1.5% FCS. Then the cells were washed with DMEM
without serum and incubated in DMEM (without phosphate) containing 0.3 mCi of [32P]orthophosphate for 5 h. The cells were
then lysed and the hemagglutinin-tagged RalA immunoprecipitated with
the 12CA5 antibody (Roche Molecular Biochemicals) coupled to protein
G-Sepharose (Amersham Biosciences, Inc.). The Sepharose resin with the
12CA5 antibody and the precipitated RalA was extensively washed, and
the remaining GTP/GDP was eluted. Both guanine nucleotides were
separated by TLC with polyethylenimin-cellulose (Merck), and
their amounts were quantified by phosphorimaging analysis
(Bio-Rad).
Immunofluorescence and Western Blots--
COS7 cells were
directly cultured on coverslips and transfected with SuperFect as
described above. 1 µg of DNA was used for transfection. After
transfection and expression of the constructs, the cells were fixed and
incubated with antibodies as described previously (54). For the
recognition of c-Myc-tagged RalGDS constructs, the monoclonal 9E10
antibody was employed (Roche Molecular Biochemicals), and for detection
of the primary antibody Alexa 594 goat -mouse (Molecular Probes) was
used. Fluorescence was observed with a Zeiss confocal microscope at
1-µm z-resolution and ×100 magnification.
Western blotting was performed according to standard procedures with a
secondary antibody conjugated to horseradish peroxidase. For the
recognition of RalGDS -Myc (Santa Cruz Biotechnologies) -RalGDS-RBD or RG139 (both kindly provided by R. Berdeaux,
Berkeley, CA) were used. Detection was carried out with ECL
luminescence (Amersham Biosciences, Inc.). Expression levels of RalGDS
in the Ral loading assay were determined in separate transfections.
Proteins--
RalGDS-RBD (formerly termed RGF97) and Rap1A were
prepared as described by Herrmann et al. (21), and the
preparation of Ras is described by Tucker et al. (33).
Loading of the Ras proteins with GppNHp (Sigma Chemical Co.) and
mantGppNHp, respectively, was performed in a buffer containing 200 mM ammonium sulfate and 2 units of alkaline phosphatase
(Roche Molecular Biochemicals) per milligram of protein. mantGppNHp was
synthesized according to John et al. (34). In the case of
Ras a 2-fold excess of the non-hydrolyzable nucleotide was added, and
in the case of Rap1A a 5-fold excess and 10 mM EDTA were
added. The solutions were incubated at 20 °C for 1 h. For a
last step of purification, all proteins were subjected to size
exclusion chromatography (Superdex 75, Amersham Biosciences, Inc.).
Protein concentrations were measured using the dye assay as described
by Bradford (35). Bovine serum albumin was used for calibration.
In Vitro Assays--
All experiments were carried out in a
buffer containing 20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM MgCl2 and 1 mM dithioerythritol. Fluorescence spectra were
recorded on a spectrofluorometer (Fluoromax, Spex) at 25 °C with an
experimental error smaller than 5% when the spectra were reproduced.
For stopped-flow measurements, an SM17 apparatus (Applied Photophysics)
was used. Rate constants can reliably be measured up to 500 s 1, because the dead time for the mixing of two solutions
is in the range of 1-2 ms. mant nucleotides were excited at 360 nm, and the fluorescence was recorded through a 408-nm cut-off filter. Ras
or Rap1A bound to mantGppNHp was mixed with RalGDS-RBD in more than
5-fold molar excess to have pseudo-first order conditions. Binding of
effectors to Ras proteins is detectable by a change of the fluorescence
of the mant nucleotide as described earlier (31, 36).
 |
RESULTS |
Ras G12V-mediated RalGDS Activation Can Be Impaired by a Single
Point Mutation within the RBD--
Previous experiments have shown the
activation of proteins of the RalGDS family by Ras (11). From the
structure of the complex between Ras and RalGDS-RBD, it became evident
that K835 (originally termed K48 in the RBD of RalGDS (37)) is one of
three major amino acids involved in the complex formation between
RalGDS-RBD and Ras proteins (38, 39). The K835A mutation reduced the binding affinities by a factor of >25 and 700 for Ras and Rap1A, respectively. This mutation was tested in the Ral loading assay (Fig.
1). We chose to analyze the ratio of GTP
over total guanine nucleotide bound to RalA, because this does not
depend on changes in the expression levels of RalA as compared with
methods, which detect only the GTP form. RalGDS and its K835A mutant
were transiently expressed in COS7 cells together with RalA and a
constitutive active version of Ras (Ras G12V). The activity of RalGDS
was measured indirectly via the GTP load on immunoprecipitated RalA. In
accordance with the results from Urano et al. (7), it is
shown that, upon co-expression of RalGDS and RalA in COS7 cells, the
GTP content on RalA is significantly increased over the basal GTP
content when RalA is expressed either alone, or together with Ras G12V in COS7 cells. However, the 23% GTP bound to RalA in the presence of
RalGDS was increased to 37% with Ras G12V. In contrast, the K835A
mutant, which was expressed at a slightly higher level than the wild
type, was hardly stimulated by Ras G12V. These results underscore the
important contribution of the RBD for the stimulation of RalGDS by
Ras.

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 1.
Effect of the mutant RalGDS K835A on the
Ras-mediated stimulation of RalGDS. In each experiment 1 µg of
pMT2:RalA was transfected. In addition, pcDNA3:RalGDS
(WT) and its K835A mutant (1 µg) and pSVK3:RasG12V (3 µg) were co-transfected as indicated. After immunoprecipitation of
RalA the bound nucleotides were separated by thin layer chromatography
and visualized by phosphorimaging (upper panel). The density
counts of the GDP and GTP spots were quantified, and the ratio of bound
GTP on RalA was calculated. The mean value and standard deviations from
three independent transfections are shown in the lower
panel. The insert shows a Western blot of RalGDS and
its K835A mutant detected by the monoclonal -RG139 antibody,
indicating comparable expression of both constructs. As seen with
marker proteins, the 99-kDa RalGDS runs in SDS-PAGE at a molecular
mass > 116 kDa. Similar observations were made by Albright
et al. (44) and possibly indicate post-translational
modifications.
|
|
RalGDS Can Be Activated by Ras Independently of Its
RBD--
In agreement with recent reports (5, 7) the experiments
described above showed that members of the RalGDS family are activated
by Ras. Rap was not able to activate RalGDS, although the affinity
between both proteins is two orders of magnitude higher than that of
RalGDS and Ras (21). To understand the difference between Ras and Rap
regarding the activation of RalGDS, we tested whether additional
activation steps are involved during the interaction between Ras and
RalGDS. To discriminate between recruitment and activation of RalGDS by
Ras, different constructs of the exchange factor were used (Fig.
2A). The C-terminal 30 amino
acids, which do not belong to the C-terminal RBD fold, were deleted
(RalGDS*), and the Ki-Ras CAAX box was attached
(RalGDS*CAAX). In addition, the RBD was deleted from RalGDS
(RalGDS RBD), and again the Ki-Ras CAAX box was tethered
to the newly formed C terminus (RalGDS RBD-CAAX).

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 2.
Expression of RalGDS variants in COS7
cells. A, the domain organization of RalGDS. It
consists of the Ras exchange motif (R), the guanine
nucleotide exchange factor motif (GEF), and the Ras binding
domain (RBD). For the mutants used in this study the
C-terminal alterations are shown. All RalGDS constructs contain a c-Myc
tag at the N terminus. B, c-Myc-tagged RalGDS constructs
were transiently transfected into COS7 cells, and their localization
was probed with the monoclonal -c-Myc antibody 9E10 and a secondary
antibody conjugated to the Alexa 594 dye. The immunofluorescence images
were obtained by confocal microscopy. The numbering of the
images is in accordance with those of the constructs shown
in A.
|
|
The localization of the different RalGDS constructs was investigated
via immunofluorescence with confocal microscopy and compared with the
wild type (Fig. 2B). For RalGDS a typical cytosolic stain could be observed in the confocal plane (image 1). A
similar staining pattern was seen for the Myc-mRalGDS* and - RBD
constructs, indicating that the truncated constructs localize to the
same cellular compartments as RalGDS (images 2 and
4). In contrast, when the CAAX-box modified versions of RalGDS were analyzed, a rim stain was observed that demonstrates the artificial recruitment to the plasma membrane (images 3 and 5).
Next, the modified RalGDS constructs were transiently
expressed in COS7 cells, and their activity was probed by the
determination of the GTP content of co-transfected RalA. In addition,
the capability of Ras G12V to stimulate the nucleotide exchange rate of
RalA via the RalGDS variants was investigated. In Fig.
3 it is seen that the RalGDS* construct,
which lacks the 30 C-terminal amino acids, behaves similarly to RalGDS
wild type in Fig. 1, i.e. the GTP content of RalA when
co-transfected with WT* can be stimulated from 25% to 35% in the
presence of Ras G12V. Western blot analysis demonstrated comparable
expression levels of the RalGDS constructs regardless of whether Ras
G12V was present or not. RalGDS*CAAX was only moderately
stimulated by Ras G12V as well as RalGDS without its RBD. In contrast,
deletion of the RBD and artificial recruitment to the plasma membrane
resulted in a construct, which was activated by Ras G12V. The latter
demonstrates an RBD-independent mechanism of RalGDS activation by
Ras.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 3.
Activation of RalGDS variants by Ras.
A, RBD-independent activation of RalGDS. 1 µg of pMT2:RalA
was co-transfected with the indicated RalGDS and Ras expression vectors
(1 µg each). The GTP content of RalA was quantified after
immunoprecipitation as described in Fig. 1. The experiments were
repeated three times, and the mean and standard deviation of the GTP
content of Ral are given. The Western blot (WB) shows the
expression levels of RalGDS probed with the -Myc antibody.
B, the switch II region of Ras is involved in the activation
of RalGDS. As under A, pMT2:RalA was co-transfected
with RalGDS RBD-CAAX as indicated. In addition, Ras G12V
and Ras G12V, Y64W mutants were co-expressed and the GTP content of
RalA was quantified. The data show a representative experiment from
three repetitions.
|
|
Ras contains two regions that change their conformations in response to
the nucleotide state of the GTPase and are called switch I and switch
II. Structural analysis demonstrated that the switch I region is mainly
responsible for recognizing the RBD of an effector. The complex
structures of PI3K and Ras clearly show that the switch II region makes
contacts with the kinase domain and helps to elevate the basal activity
of the lipid kinase (30). Encouraged by these findings, we tested an
activated mutant of Ras in this region (Ras G12V, Y64W) in the RalGDS
activation assay (Fig. 3B). This mutant did not stimulate
RalGDS RBD-CAAX as efficiently as did Ras G12V, indicating
the involvement of the switch II region in the activation of
RalGDS.
Influence of Rap1 on the Activation of RalGDS--
Rap1 had been
described as an antagonist of Ras (13-19). Therefore, we tested
whether it can block the Ras-mediated activation of RalGDS. When
constitutively active Rap1A G12V was transiently transfected together
with RalGDS-WT* or RalGDS RBD-CAAX, it is seen that the
RBD is required for a decrease of the exchange activity (Fig.
4). The block of signal transmission was
seen in the non-stimulated and Ras G12V-stimulated case. Western blot
analysis of the RalGDS expression levels showed comparable levels in
all assays. The presence of the RBD is crucial for an Rap1-mediated
effect on Ras signaling via RalGDS.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 4.
Influence of Rap1 on the Ras and
RalGDS-mediated nucleotide exchange on RalA. 1 µg of
pcDNA3:RalGDS* and 1 µg of
pcDNA3:RalGDS RBD-CAAX, respectively, was
co-transfected with 1 µg of pMT2:RalA into COS7 cells. In addition,
pSVK3:Ras G12V and pcDNA3:Rap1A G12V (1 µg) were co-transfected.
The nucleotide load on RalA was determined as described in Fig. 1. The
columns represent the mean and standard deviations of the
GTP content on RalA of three independent experiments. Note that the
data for the transfections without Rap1A G12V were taken from Fig. 3 to
compare the influences of Rap1 on RalGDS activity. The Western blot
(WB) shows the expression levels of RalGDS probed with the
-Myc antibody.
|
|
Dynamics of the Interaction between RBDs and Ras
Proteins--
Depending on its GTPase binding partner, RalGDS is
either activated or inhibited. Rap seems to sequester RalGDS into an
inactive complex. To further understand the result of a parallel
activation of Ras and Rap, we investigated the specificity of the
RalGDS-RBD with stopped-flow experiments. To follow the binding between
the GTPases and RalGDS-RBD, we employed a fluorescent nucleotide
(mantGppNHp) as described previously (31, 36). Upon binding of
RalGDS-RBD to Ras or to Rap complexed with mantGppNHp, a decrease in
fluorescence was observed (Fig. 5,
upper panel). The RalGDS-RBD concentration was in more than
5-fold molar excess over the GTPases; therefore, the fluorescence
traces could be fitted according to pseudo-first order kinetics by a
single-exponential equation yielding the observed rate constant
kobs. The bimolecular association constant
kon was obtained from the slope of the linear
regression of kobs plotted versus
RalGDS-RBD concentration (Table I). The
dissociation rate constant koff corresponds to
the intercept value. koff is 10 s 1
for the dissociation of the Ras·RalGDS-RBD complex and close to zero
for the Rap·RalGDS system. To ensure that determination of
kon is not obscured by saturation at higher
RalGDS-RBD concentrations, only concentrations up to 15 µM RBD were included in the calculations above. Similar
to other effector RBDs (31, 36), saturation of the binding kinetics was
observed at higher concentrations (Fig. 5, lower panel), and
these data can be described with the hyperbolic equation 1 yielding
k+2 and K1.
k 2 corresponds to koff
from the linear approach at low concentrations (see above),
|
(Eq. 1)
|
As with other effectors like AF6- and Raf-RBD (31, 36), this
behavior may be interpreted as a two-step complex formation. For the
interaction of Ras·mantGppNHp and RalGDS-RBD, the dissociation equilibrium constant for the first step is K1 = 61 µM. The overall rate is limited to 300 s 1 by the rate constant k2 for the
second step, which presumably corresponds to a conformational
rearrangement. These observations reflect the structural similarity of
effector·RBD/Ras complexes. The experimental error for the
k2 value is estimated to 10%, whereas for
K1 the error is 20%, because errors, both in
the fit and in the determination of the concentration, must be
considered. For the Rap1·RalGDS-RBD system, no saturation of
kobs was detected up to rates of 500 s 1 at 100 µM RalGDS-RBD, suggesting a much
weaker initial complex.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 5.
Kinetics of Ras·RalGDS-RBD
interaction. A, the association of 2.5 µM
RalGDS-RBD and 0.5 µM Ras·mantGppNHp was measured at
25 °C by stopped-flow, and an exponential curve was fitted to the
data yielding kobs (decreasing fluorescence).
The dissociation of a complex of 2.5 µM RalGDS-RBD and
0.5 µM Ras·mantGppNHp was initiated with 60 µM Ras·GppNHp. The resulting change in fluorescence was
fitted with an exponential curve to determine
koff (increasing fluorescence). The
insert shows the change of fluorescence when 0.5 µM Ras were mixed with 50 µM RalGDS-RBD.
All spectra were corrected with the buffer blank. 1,
Ras·mantGppNHp; 2, Ras·mantGppNHp and RalGDS-RBD;
3, Ras·mantGDP; 4, Ras·mantGDP and
RalGDS-RBD. B, saturation of the
kobs values at higher RalGDS-RBD
concentrations at 10 °C. The curve is the result of
a fit to the data according to Equation 1.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Association and dissociation rate constants for Ras and Rap1A
interacting with RalGDS-RBD
The KD value is calculated from the ratio of the
rate constants. The experimental error on rate constants is 10%. For
comparison available data for Raf-RBD and AF6-RBD are included (31,
36).
|
|
Due to its small value, the dissociation rate constant of RBD·GTPase
complexes cannot be determined precisely from the intercept as
described above. Therefore we employed displacement experiments to
obtain this value more reliably. The equilibrated complex
Ras·mantGppNHp·RalGDS-RBD was rapidly mixed with a large excess
(>100-fold) of Ras bound to non-labeled GppNHp to sequester
RalGDS-RBD. Under these conditions the change of the fluorescence
intensity is governed by the dissociation of RalGDS-RBD from
Ras·mantGppNHp, and koff can be derived
thereof with a 10% error. The corresponding dissociation rate constant for the Rap1 complex was determined as well.
Table I summarizes the results of the interactions between
RalGDS-RBD and Ras or Rap1 at 25 °C and compares them with AF6- and
Raf-RBD. Despite the large differences in the KD values, which vary by a factor of 400, it can be seen that the association rate constants lie close together (within a 5-fold variation). The differential affinities of the complexes are achieved mainly by the dissociation rate constants, which vary by a factor of
600. These results show that the different effector·GTPase complexes
form at similar rates and that the varying affinities are due to
largely different dissociation rates leading to different lifetimes
(defined as inverse dissociation rate constant) of the complexes. The
lifetime of the low affinity Ras·RalGDS-RBD complex is about 0.1 s. In contrast, the Rap1·RalGDS-RBD complex is more stable with a
lifetime of 10 s.
 |
DISCUSSION |
We have characterized a series of mutants to elucidate the reason
for the specificity of the activation of RalGDS by Ras. A single point
mutation within the RBD of RalGDS, which weakens the interaction to Ras
more than 25-fold, almost completely disrupted the stimulation of
RalGDS by Ras. On the contrary, a RalGDS protein, which was
artificially targeted to the plasma membrane and lacked the RBD, could
be activated by Ras, and the switch II region of Ras was involved in
the activation of the effector. When Rap1A G12V is co-transfected with
RalGDS, only the constructs containing the RBD are inhibited in their
ability to activate RalA by Rap. Stopped-flow measurements demonstrate
that the formation of the complex between effector RBDs and the
GTP-form of Ras or Rap1 occurs in a comparable time frame, although
large variations in the affinity exist. This binding specificity is
achieved via largely differing dissociation rates. Active Rap1 can hold
RalGDS-RBD especially long in the complexed state.
The observations, that Ras but not Rap1 is able to stimulate the RalGDS
activity and that Rap1 binds a hundred times more tightly to
RalGDS-RBD, encouraged us to elucidate the activation mechanism of
RalGDS in more detail. In accordance with the data of Urano et
al. (7), we could demonstrate with the mutant RalGDS K835A that
the RBD of RalGDS is required for Ras-mediated activation. The major
effect of this interaction is thought to be the recruitment of the
effector to the plasma membrane. However, the observed stimulation of
the membrane-targeted RalGDS RBD-CAAX construct by Ras
shows that recruitment of RalGDS to the plasma membrane is not the only
mechanism of RalGDS activation. We were able to demonstrate this
RBD-independent activation of RalGDS by Ras, because the recruitment of
RalGDS by Ras via the RBD was separated from the subsequent activation.
In contrast, RalGDS*-CAAX showed an elevated basal activity
and could only be stimulated to a small degree. This effect might be
explained by the fact that the GDP form of the Ras proteins still has
some affinity for the effectors (40)2: The artificial
membrane recruitment of RalGDS*-CAAX most likely facilitates
the association between endogenous Ras in its GDP form and
RalGDS*-CAAX, thereby explaining the high basal activity and
the apparent unresponsiveness to Ras G12V. The nature of the additional
function of Ras in this activation process involves the switch II
region of Ras. It is conceivable that there are low affinity contacts
between the switch II region of Ras and RalGDS, which enhance the
exchange activity of the GEF domain. Such contacts were proposed in a
complex between RalGDS RBD and Ras (38) but could not be confirmed by
us (39). However, this activation scenario would parallel the findings
for Raf-kinase and PI3K, which also become activated when bound to Ras
(30, 41, 42). Alternatively, there could be an unidentified factor, which is controlled by Ras and acts positively on RalGDS.
The stimulatory effect observed in addition to membrane recruitment
could rely on relieving inhibitory signals (37). Support for inhibitory
signals acting on the GEF moiety of RalGDS comes from Rsc (12, 43). It
has been demonstrated that transforming properties of this fusion
protein are due to the Rgr region. Rgr lacks both N and C termini as
observed in the other RalGDS family members and, therefore, may have
lost an autoinhibitory signal.
The comparison of stopped-flow measurements of the complex formation
between RBDs from RalGDS, Raf, and AF6 and the GTPases Ras and Rap1
revealed that the binding specificity is mainly achieved by variation
of the dissociation rates. Conversely, for the Ras/Raf-RBD system it
has recently been demonstrated that effector recognition by the GTP and
GDP forms, respectively, is differentiated by the association process,
i.e. the GTPase switch is designed to prevent an association
between the GDP form of Ras and an effector (31). Taken together,
recognition by the effector of GTPase switch position should be
interpreted in terms of association rate constants in which Raf, the
paradigm of a Ras effector, differs little from RalGDS. The lifetime of
the complex between RalGDS-RBD and Ras is about 0.1 s. This should
be long enough to enable other processes like small conformational
changes and phosphorylation events. It is interesting that RalGDS is
indeed phosphorylated (44). So far, no correlation between the activity
of RalGDS and its phosphorylation state could be demonstrated.
Rap1 is described originally as a Ras antagonist (13-19). The observed
slow dissociation rate between Rap1 and RalGDS-RBD could explain the
Ras-antagonistic effect on a molecular level. Currently, no other Ras
effector is described that has such a high affinity and, therefore, a
slow dissociation rate constant as RalGDS-RBD and Rap1. We therefore
speculate that inhibitory effects of Rap1 on Ras might be due mainly to
a competition between these proteins for RalGDS. This hypothesis is
corroborated by the necessity of the presence of RBD in RalGDS for Rap1
inhibition as observed in this study. In PC12 cells Ras signaling via
Raf and PI3K mediates cell cycle arrest and differentiation of the
cells into a neural cell type, but signaling via RalGDS leads to
proliferation (10). These two opposing effects of Ras effector
signaling require additional controls of the effectors. Sequestration
of RalGDS by Rap1 would be one mechanism to control the flow of signals
coming from Ras and supports observed Rap1 functions in differentiation
(45-49). It should be noted that in NIH3T3 and Rat1 fibroblasts no
inhibitory effect of Rap1 on RalA was observed (50). It is not clear if these differences are due to the sensitivity of the different assay
systems or reflect special features of this kind of fibroblasts. Our
data attempt to explain the influence of Rap1 on Ras transformation on
a molecular level. However, they do not exclude RalGDS-independent functions of Rap, which might be transmitted by other effector proteins
(20).
RalGDS belongs to the group of exchange factors with a Cdc25 homology
domain. It has been demonstrated that another member of this family,
Sos, is inhibited in its exchange activity via the C and N termini
(51). This and our findings could indicate a general mechanism of GEFs
homologous to Cdc25. In addition, findings with GEFs of other families
of the small GTPases like the Dbl-homology domain containing Rho GEFs
(52) and the Sec7-homology domain containing Arf GEFs (53), where PH
domains are thought to regulate the exchange domain, give rise to a
general picture in which GEF activity is down-modulated in the
non-stimulated state. The physiological relevance of an actively
inhibited GEF might be a decreased spontaneous activation of Ral.
The data presented here show the importance of the RBD in RalGDS
for activation by Ras as well as for the inhibition by Rap1. In
addition to RBD-mediated membrane recruitment by Ras, another component
of activation, involving the switch II region of Ras, is indicated. Our
kinetic data suggest a role of interaction dynamics for specific signal
transduction. To further understand signal transmission by RalGDS, it
will be necessary to determine the nature of the observed
RBD-independent activation. Employing RalGDS variants, which are
deficient of either Ras binding or activation, should also shed light
on the benefits of an activation mechanism of RalGDS for signaling of
Ras proteins under different physiological conditions.
 |
ACKNOWLEDGEMENTS |
We thank Fried Zwartkruis, Rob Wolthuis, and
Hans Bos for constructs and discussion. We also thank R. Berdeaux and
C. Block for reagents, A. Wittinghofer for constant support, and Dan
Irwin for critical comments on the manuscript.
 |
FOOTNOTES |
*
This work was supported by a grant from the Deutsche
Forschungsgemeinschaft (SFB394) (to C. H.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The on-line version of this article (available at
www.jbc.org) contains Fig. S1.
Present address: Howard Hughes Medical Institute, Mt. Zion Cancer
Center, UCSF Box 0703, 3rd and Parnassus Ave., San Francisco, CA 94143.
§
To whom correspondence should be addressed: Tel.: 49-231-133-2160;
Fax: 49-231-133-2199; E-mail:
christian.herrmann@mpi-dortmund.mpg.de.
Published, JBC Papers in Press, December 17, 2001, DOI 10.1074/jbc.M110800200
2
C. Herrmann, unpublished observations.
 |
ABBREVIATIONS |
The abbreviations used are:
PI3K, phosphatidylinositol 3-kinase;
RalGDS, Ral guanine nucleotide
dissociation stimulator;
GEF, guanine-nucleotide exchange factor;
RBD, Ras binding domain;
DMEM, Dulbecco's modified Eagle's medium;
FCS, fetal calf serum.
 |
REFERENCES |
| 1.
|
McCormick, F.,
and Wittinghofer, A.
(1996)
Curr. Opin. Biotechnol.
7,
449-456[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Joneson, T.,
and Bar-Sagi, D.
(1997)
J. Mol. Med.
75,
587-593[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Sun, H.,
Tonks, N. K.,
and Bar-Sagi, D.
(1994)
Science
266,
285-288[Abstract/Free Full Text]
|
| 4.
|
Jimenez, C.,
Jones, D. R.,
Rodriguezviciana, P.,
Gonzalezgarcia, A.,
Leonardo, E.,
Wennstrom, S.,
Vonkobbe, C.,
Toran, J. L.,
Borlado, L. R.,
Calvo, V.,
Copin, S. G.,
Albar, J. P.,
Gaspar, M. L.,
Diez, E.,
Marcos, M. A. R.,
Downward, J.,
Martinez, C.,
Merida, I.,
and Carrera, A. C.
(1998)
EMBO J.
17,
743-753[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Wolthuis, R. M. F.,
de Ruiter, N. D.,
Cool, R. H.,
and Bos, J. L.
(1997)
EMBO J.
16,
6748-6761[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Khwaja, A.,
Rodriguez-Viciana, P.,
Wennstrom, S.,
Warne, P. H.,
and Downward, J.
(1997)
EMBO J.
16,
2783-2793[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Urano, T.,
Emkey, R.,
and Feig, L. A.
(1996)
EMBO J.
15,
810-816[Medline]
[Order article via Infotrieve]
|
| 8.
|
Franza, B. R.,
Maruyama, K.,
Garrels, J. I.,
and Ruley, H. E.
(1986)
Cell
44,
409-418[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Wood, K. W.,
Sarnecki, C.,
Roberts, T. M.,
and Blenis, J.
(1992)
Cell
68,
1041-1050[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Goi, T.,
Rusanescu, G.,
Urano, T.,
and Feig, L. A.
(1999)
Mol. Cell. Biol.
19,
1731-1741[Abstract/Free Full Text]
|
| 11.
|
Wolthuis, R. M. F.,
and Bos, J. L.
(1999)
Curr. Opin. Genet. Dev.
9,
112-117[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
D'Adamo, D. R.,
Novick, S.,
Kahn, J. M.,
Leonardi, P.,
and Pellicier, A.
(1997)
Oncogene
14,
1295-1305[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Kitayama, H.,
Sugimoto, Y.,
Matsuzaki, T.,
Ikawa, Y.,
and Noda, M.
(1989)
Cell
56,
77-84[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Leach, S. D.,
Berger, D. H.,
Davidson, B. S.,
Curley, S. A.,
and Tainsky, M. A.
(1998)
Pancreas
16,
491-498[Medline]
[Order article via Infotrieve]
|
| 15.
|
Damak, S.,
Harnboonsong, Y.,
George, P. M.,
and Bullock, D. W.
(1996)
Mol. Carcinog.
17,
84-91[Medline]
[Order article via Infotrieve]
|
| 16.
|
Kondoh, N.,
Noda, M.,
Fisher, R. J.,
Schweinfest, C. W.,
Papas, T. S.,
Kondoh, A.,
Samuel, K. P.,
and Oikawa, T.
(1996)
Biochim. Biophys. Acta
1313,
41-46[Medline]
[Order article via Infotrieve]
|
| 17.
|
Burney, T. L.,
Rockove, S.,
Eiseman, J. L.,
Jacobs, S. C.,
and Kyprianou, N.
(1994)
Prostate
25,
177-188[Medline]
[Order article via Infotrieve]
|
| 18.
|
Sakoda, T.,
Kaibuchi, K.,
Kishi, K.,
Kishida, S.,
Doi, K.,
Hoshino, M.,
Hattori, S.,
and Takai, Y.
(1992)
Oncogene
7,
1705-1711[Medline]
[Order article via Infotrieve]
|
| 19.
|
Caamano, J.,
DiRado, M.,
Iizasa, T.,
Momiki, S.,
Fernandes, E.,
Ashendel, C.,
Noda, M.,
and Klein-Szanto, A. J.
(1992)
Mol. Carcinog.
6,
252-259[Medline]
[Order article via Infotrieve]
|
| 20.
|
Bos, J. L.,
de Rooij, J.,
and Reedquist, K. A.
(2001)
Nature Rev.
2,
369-377
|
| 21.
|
Herrmann, C.,
Horn, G.,
Spaargaren, M.,
and Wittinghofer, A.
(1996)
J. Biol. Chem.
271,
6794-6800[Abstract/Free Full Text]
|
| 22.
|
Kishida, S.,
Koyama, S.,
Matsubara, K.,
Kishida, M.,
Matsuura, Y.,
and Kikuchi, A.
(1997)
Oncogene
15,
2899-2907[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Matsubara, K.,
Kishida, S.,
Matsuura, Y.,
Kitayama, H.,
Noda, M.,
and Kikuchi, A.
(1999)
Oncogene
18,
1303-1312[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Beranger, F.,
Goud, B.,
Tavitian, A.,
and de Gunzberg, J.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
1606-1610[Abstract/Free Full Text]
|
| 25.
|
Pizon, V.,
Desjardins, M.,
Bucci, C.,
Parton, R. G.,
and Zerial, M.
(1994)
J. Cell Sci.
107,
1661-1670[Abstract]
|
| 26.
|
Maridonneau-Parini, I.,
and De Gunzburg, J.
(1992)
J. Biol. Chem.
267,
6396-6402[Abstract/Free Full Text]
|
| 27.
|
Berger, G.,
Quarck, R.,
Tenza, D.,
Levy-Toledano, S., De,
Gunzburg, J.,
and Cramer, E. M.
(1994)
Br. J. Haematol.
88,
372-382[Medline]
[Order article via Infotrieve]
|
| 28.
|
Feig, L. A.,
Urano, T.,
and Cantor, S.
(1996)
Trends Biochem. Sci.
21,
438-441[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Morrison, D. K.,
and Cutler, R. E.
(1997)
Curr. Opin. Cell Biol.
9,
174-179[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Pacold, M. E.,
Suire, S.,
Perisic, O.,
Lara-Gonzalez, S.,
Davis, C. T.,
Walker, E. H.,
Hawkins, P. T.,
Stephens, L.,
Eccleston, J. F.,
and Williams, R. L.
(2000)
Cell
103,
931-943[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Sydor, J. R.,
Engelhard, M.,
Wittinghofer, A.,
Goody, R. S.,
and Herrmann, C.
(1998)
Biochemistry
37,
14292-14299[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Picard, V.,
Ersdal-Badju, E., Lu, A.,
and Bock, S. C.
(1994)
Nucleic Acids Res.
22,
2587-2591[Abstract/Free Full Text]
|
| 33.
|
Tucker, J.,
Sczakiel, G.,
Feuerstein, J.,
John, J.,
Goody, R. S.,
and Wittinghofer, A.
(1986)
EMBO J.
5,
1351-1358[Medline]
[Order article via Infotrieve]
|
| 34.
|
John, J.,
Sohmen, R.,
Feuerstein, J.,
Linke, R.,
Wittinghofer, A.,
and Goody, R. S.
(1990)
Biochemistry
29,
6058-6065[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Bradford, M. M.
(1976)
Anal. Biochem.
72,
248-254[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Linnemann, T.,
Geyer, M.,
Jaitner, B. K.,
Block, C.,
Kalbitzer, H. R.,
Wittinghofer, A.,
and Herrmann, C.
(1999)
J. Biol. Chem.
274,
13556-13562[Abstract/Free Full Text]
|
| 37.
|
Geyer, M.,
Herrmann, C.,
Wohlgemuth, S.,
Wittinghofer, A.,
and Kalbitzer, H. R.
(1997)
Nat. Struct. Biol.
4,
694-699[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Huang, L.,
Hofer, F.,
Martin, G. S.,
and Kim, S. H.
(1998)
Nat. Struct. Biol.
5,
422-426[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Vetter, I. R.,
Linnemann, T.,
Wohlgemuth, S.,
Geyer, M.,
Kalbitzer, H. R.,
Herrmann, C.,
and Wittinghofer, A.
(1999)
FEBS Let.
451,
175-180[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Herrmann, C.,
Martin, G. A.,
and Wittinghofer, A.
(1995)
J. Biol. Chem.
270,
2901-2905[Abstract/Free Full Text]
|
| 41.
|
Stokoe, D.,
and McCormick, F.
(1997)
EMBO J.
16,
2384-2396[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Tamada, M., Hu, C. D.,
Kariya, K.,
Okada, T.,
and Kataoka, T.
(1997)
Oncogene
15,
2959-2964[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Hernandez-Munoz, I.,
Malumbres, M.,
Leonardi, P.,
and Pellicer, A.
(2000)
Oncogene
19,
2745-2757[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Albright, C. F.,
Giddings, B. W.,
Liu, J.,
Vito, M.,
and Weinberg, R. A.
(1993)
EMBO J.
12,
339-347[Medline]
[Order article via Infotrieve]
|
| 45.
|
Hariharan, I. K.,
Carthew, R. W.,
and Rubin, G. M.
(1991)
Cell
67,
717-722[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Chant, J.,
Corrado, K.,
Pringle, J. R.,
and Herskowitz, I.
(1991)
Cell
65,
1213-1224[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Rebstein, P. J.,
Cardelli, J.,
Weeks, G.,
and Spiegelman, G. B.
(1997)
Exp. Cell Res.
231,
276-283[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Ito, S.,
Matsui, Y.,
Toh-e, A.,
Harashima, T.,
and Inoue, H.
(1997)
Mol. Gen. Genet.
255,
429-437[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Yoshida, Y.,
Kawata, M.,
Miura, Y.,
Musha, T.,
Sasaki, T.,
Kikuchi, A.,
and Takai, Y.
(1992)
Mol. Cell. Biol.
12,
3407-3414[Abstract/Free Full Text]
|
| 50.
|
Zwartkruis, F. J. T.,
Wolthuis, R. M. F.,
Nabben, N. M. J. M.,
Franke, B.,
and Bos, J. L.
(1998)
EMBO J.
17,
5905-5912[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Corbalan-Garcia, S.,
Margarit, S. M.,
Galron, D.,
Yang, S. S.,
and Barsagi, D.
(1998)
Mol. Cell. Biol.
18,
880-886[Abstract/Free Full Text]
|
| 52.
|
Han, J. W.,
Lubyphelps, K.,
Das, B.,
Shu, X. D.,
Xia, Y.,
Mosteller, R. D.,
Krishna, U. M.,
Falck, J. R.,
White, M. A.,
and Broek, D.
(1998)
Science
279,
558-560[Abstract/Free Full Text]
|
| 53.
|
Klarlund, J. K.,
Rameh, L. E.,
Cantley, L. C.,
Buxton, J. M.,
Holik, J. J.,
Sakelis, C.,
Patki, V.,
Corvera, S.,
and Czech, M. P.
(1998)
J. Biol. Chem.
273,
1859-1862[Abstract/Free Full Text]
|
| 54.
|
van Weering, D. H. J.,
and Bos, J. L.
(1997)
J. Biol. Chem.
272,
249-254[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. G. Rondaij, R. Bierings, E. L. van Agtmaal, K. A. Gijzen, E. Sellink, A. Kragt, S. S. G. Ferguson, K. Mertens, M. J. Hannah, J. A. van Mourik, et al.
Guanine exchange factor RalGDS mediates exocytosis of Weibel-Palade bodies from endothelial cells
Blood,
July 1, 2008;
112(1):
56 - 63.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. He, I. Gomes, T. Nguyen, G. Jayaram, P. T. Ram, L. A. Devi, and R. Iyengar
The G{alpha}o/i-coupled Cannabinoid Receptor-mediated Neurite Outgrowth Involves Rap Regulation of Src and Stat3
J. Biol. Chem.,
September 30, 2005;
280(39):
33426 - 33434.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Ling, T. Zhu, and P. E. Lobie
Src-CrkII-C3G-dependent Activation of Rap1 Switches Growth Hormone-stimulated p44/42 MAP Kinase and JNK/SAPK Activities
J. Biol. Chem.,
July 11, 2003;
278(29):
27301 - 27311.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|